{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:33:47Z","timestamp":1792640027451,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40264-014-0206-3","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T05:19:43Z","timestamp":1407215983000},"page":"693-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tolerability and Safety of the New Anti-Obesity Medications"],"prefix":"10.1007","volume":"37","author":[{"given":"Vojtech","family":"Hainer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Aldhoon-Hainerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,6]]},"reference":[{"key":"206_CR1","unstructured":"World Health Organization. Media centre. Obesity and overweight. Fact sheet no. 311, updated March 2013. http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/ . Accessed 21 July 2014"},{"key":"206_CR2","unstructured":"World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation (WHO Technical Report Series 894). Geneva: WHO Consultation on Obesity; 2000. pp. 1\u2013153"},{"key":"206_CR3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000126822","volume":"1","author":"C Tsigos","year":"2008","unstructured":"Tsigos C, Hainer V, Basdevant A, et al. Obesity Management Task Force of the European Association for the Study of Obesity. Management of obesity in adults: European clinical practice guidelines. Obes Facts. 2008;1:106\u201316.","journal-title":"Obes Facts."},{"key":"206_CR4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000355480","volume":"6","author":"M Fried","year":"2013","unstructured":"Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6:449\u201368.","journal-title":"Obes Facts."},{"key":"206_CR5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2337\/dc06-1569","volume":"30","author":"M Freemark","year":"2007","unstructured":"Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care. 2007;30:395\u2013402.","journal-title":"Diabetes Care."},{"key":"206_CR6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"RR Wing","year":"2013","unstructured":"Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145\u201354.","journal-title":"N Engl J Med."},{"key":"206_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","volume":"22","author":"Look AHEAD Research Group","year":"2014","unstructured":"Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22:5\u201313.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR8","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","volume":"283","author":"JM Gardin","year":"2000","unstructured":"Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine. JAMA. 2000;283:1703\u20139.","journal-title":"JAMA."},{"key":"206_CR9","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007;370:1706\u201313.","journal-title":"Lancet."},{"key":"206_CR10","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905\u201317.","journal-title":"N Engl J Med."},{"key":"206_CR11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155\u201361.","journal-title":"Diabetes Care."},{"issue":"Suppl 2","key":"206_CR12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/dmrr.2349","volume":"28","author":"V Hainer","year":"2012","unstructured":"Hainer V, Aldhoon Hainerov\u00e1 I. Do we need anti-obesity drugs? Diabetes Metab Res Rev. 2012;28(Suppl 2):8\u201320.","journal-title":"Diabetes Metab Res Rev."},{"key":"206_CR13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMp1211277","volume":"367","author":"E Colman","year":"2012","unstructured":"Colman E, Golden J, Roberts M, et al. The FDA\u2019s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577\u20139.","journal-title":"N Engl J Med."},{"key":"206_CR14","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2011","unstructured":"Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2011;20:330\u201342.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR15","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, et al. Effect of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-contolled, phase 3 trial. Lancet. 2011;377:1341\u201352.","journal-title":"Lancet."},{"key":"206_CR16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297\u2013308.","journal-title":"Am J Clin Nutr."},{"key":"206_CR17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith SR, Weissman NJ, Anderson CM, Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245\u201356.","journal-title":"N Engl J Med."},{"key":"206_CR18","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","volume":"96","author":"MC Fidler","year":"2011","unstructured":"Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067\u201377.","journal-title":"J Clin Endocrinol Metab."},{"key":"206_CR19","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","volume":"20","author":"PM O\u2019Neil","year":"2012","unstructured":"O\u2019Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the Bloom-DM study. Obesity (Silver Spring). 2012;20:1426\u201336.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR20","first-page":"523","volume":"5","author":"JA Rider","year":"1963","unstructured":"Rider JA, Moeller HC. Double-blind evaluation of the use of phentermine in treating obesity. Appl Ther. 1963;5:523\u20134.","journal-title":"Appl Ther."},{"key":"206_CR21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/oby.20596","volume":"22","author":"JP Block","year":"2014","unstructured":"Block JP, Choudhry NK, Carpenter DP, et al. Time series analyses of the effect of FDA communications on use of prescription weight loss medications. Obesity (Silver Spring). 2014;22:943\u20139.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1528-1157.1996.tb00606.x","volume":"37","author":"E Ben-Menachem","year":"1996","unstructured":"Ben-Menachem E, Henriksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996;37:539\u201343.","journal-title":"Epilepsia."},{"key":"206_CR23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jc.2010-1848","volume":"96","author":"CK Martin","year":"2011","unstructured":"Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96:837\u201345.","journal-title":"J Clin Endocrinol Metab."},{"key":"206_CR24","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21:2163\u201371.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR25","first-page":"397","volume":"16","author":"DJ Goldstein","year":"1992","unstructured":"Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397\u2013415.","journal-title":"Int J Obes Relat Metab Disord."},{"key":"206_CR26","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.5665\/sleep.2204","volume":"35","author":"DH Winslow","year":"2012","unstructured":"Winslow DH, Bowden CH, DiDonato KP, et al. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35:1529\u201339.","journal-title":"Sleep."},{"key":"206_CR27","doi-asserted-by":"crossref","unstructured":"Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended-release. Diabetes Care. 2014;37:912\u201321.","DOI":"10.2337\/dc13-1518"},{"key":"206_CR28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.amjcard.2012.12.038","volume":"111","author":"MH Davidson","year":"2013","unstructured":"Davidson MH, Tonstad S, Oparil S, et al. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index \u226527\u00a0kg\/m2. Am J Cardiol. 2013;111:1131\u20138.","journal-title":"Am J Cardiol."},{"key":"206_CR29","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1586\/erc.10.125","volume":"8","author":"H Bays","year":"2010","unstructured":"Bays H. Phetermine, topiramate and their combination for the treatment of adiposopathy (\u2018sick fat\u2019) and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8:1777\u201381.","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"206_CR30","unstructured":"Adipex-P (phentermine) prescribing information. Philadelphia: Teva Pharmaceuticals USA, Inc.; 2012."},{"key":"206_CR31","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","volume":"19","author":"EJ Hendricks","year":"2011","unstructured":"Hendricks EJ, Greenway FL, Westman EC, et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Sliver Spring). 2011;19:2351\u201360.","journal-title":"Obesity (Sliver Spring)."},{"key":"206_CR32","first-page":"131","volume":"6","author":"JH Shin","year":"2013","unstructured":"Shin JH, Gadde KM. Clinical utility of phentermine\/topiramate (QsymiaTM) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013;6:131\u20139.","journal-title":"Diabetes Metab Syndr Obes."},{"key":"206_CR33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/HJH.0000000000000145","volume":"32","author":"J Jordan","year":"2014","unstructured":"Jordan J, Astrup A, Engeli S, et al. Cardiovascular effects of phentemine and topiramate: a new drug combination for the treatment of obesity. J Hypertens. 2014;32:1178\u201388.","journal-title":"J Hypertens."},{"key":"206_CR34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.26.3.375","volume":"26","author":"RG Wenzel","year":"2006","unstructured":"Wenzel RG, Schwarz K, Padiyara RS. Topiramate for migraine prevention. Pharmacotherapy. 2006;26:375\u201387.","journal-title":"Pharmacotherapy."},{"key":"206_CR35","doi-asserted-by":"crossref","first-page":"405.e1","DOI":"10.1016\/j.ajog.2012.07.008","volume":"207","author":"AV Margulis","year":"2012","unstructured":"Margulis AV, Mitchell AA, Gilboa SM. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207:405.e1\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"206_CR36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5301\/EJO.2010.5979","volume":"21","author":"C Issum Van","year":"2011","unstructured":"Van Issum C, Mavrakanas N, Schutz JS, Shaarawy T. Topiramate-induced acute bilateral angle closure and myopia: pathophysiology and treatment controversies. Eur J Ophthalmol. 2011;21:404\u20139.","journal-title":"Eur J Ophthalmol."},{"key":"206_CR37","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCIMAGING.112.000128","volume":"6","author":"NJ Weissman","year":"2013","unstructured":"Weissman NJ, Sanchez M, Koch GG, et al. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Circ Cardiovasc Imaging. 2013;6:560\u20137.","journal-title":"Circ Cardiovasc Imaging."},{"issue":"10","key":"206_CR38","doi-asserted-by":"crossref","first-page":"E1542","DOI":"10.1016\/S0735-1097(13)61542-9","volume":"61","author":"HB Panchal","year":"2013","unstructured":"Panchal HB, Patel P, Patel B, et al. Worsening of pre-existing valvulopathy with a new obesity drug lorcaserin, a selective 5-hydroxytryptamine 2c receptor agonist: a meta-analysis of randomized controlled trials [poster]. J Am Coll Cardiol. 2013;61(10):E1542.","journal-title":"J Am Coll Cardiol."},{"key":"206_CR39","unstructured":"Belviq (lorcaserin HCL) highlights of prescribing information. https:\/\/www.belviq.com\/document\/Belviq_Prescribing_information.pdf . Accessed 21 July 2014"},{"key":"206_CR40","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199708283370904","volume":"337","author":"EJ Mark","year":"1997","unstructured":"Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 1997;337:602\u20136.","journal-title":"N Engl J Med."},{"key":"206_CR41","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijo.0803446","volume":"31","author":"P Kopelman","year":"2007","unstructured":"Kopelman P, Bryson A, Hickling R, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007;31:494\u20139.","journal-title":"Int J Obes (Lond)."},{"key":"206_CR42","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/oby.2009.155","volume":"18","author":"P Kopelman","year":"2010","unstructured":"Kopelman P, Groot Gde H, Rissanen A, et al. Weight loss, HBA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010;18:108\u201315.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR43","unstructured":"Takeda Pharmaceutical Company Limited News Release, September 20, 2013. Norgine and Takeda announced the new drug application of OBLEAN\u00ae (generic name: cetilistat) tablets 120\u00a0mg in Japan for the treatment of obesity with complications. http:\/\/www.takeda.com\/news\/2013\/20130920_5991.html . Accessed 21 July 2014"},{"key":"206_CR44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka F, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595\u2013605.","journal-title":"Lancet."},{"key":"206_CR45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR\/bupropion SR combination as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110\u201320.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR46","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935\u201343.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR47","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022\u20139.","journal-title":"Diabetes Care."},{"key":"206_CR48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2\u00a0years with once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843\u201354.","journal-title":"Int J Obes (Lond)"},{"key":"206_CR49","unstructured":"Company announcement No 39\/2013 \u2013 Novo Nordisk. http:\/\/www.novonordisk.com\/include\/asp\/exe_news_attachment.asp?sAttachmentGUID=3f254ec7-lb91-4334-bf0d-572d4e6a4c3e . Accessed 21 July 2014"},{"key":"206_CR50","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"T Wadden","year":"2013","unstructured":"Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443\u201351.","journal-title":"Int J Obes (Lond)."},{"key":"206_CR51","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1475-2840-12-130","volume":"12","author":"JR Petrie","year":"2013","unstructured":"Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol. 2013;12:130.","journal-title":"Cardiovasc Diabetol."},{"key":"206_CR52","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","volume":"353","author":"TA Wadden","year":"2005","unstructured":"Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111\u201320.","journal-title":"N Engl J Med."},{"key":"206_CR53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1517\/14740338.2013.806481","volume":"12","author":"WT Garvey","year":"2013","unstructured":"Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf. 2013;12:741\u201356.","journal-title":"Expert Opin Drug Saf."},{"issue":"Suppl. 2","key":"206_CR54","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.2337\/dc08-s265","volume":"31","author":"V Hainer","year":"2008","unstructured":"Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: what fits whom? Diabetes Care. 2008;31(Suppl. 2):S269\u201377.","journal-title":"Diabetes Care."},{"key":"206_CR55","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/oby.20429","volume":"21","author":"BA Liang","year":"2013","unstructured":"Liang BA, Mackey TK, Archer-Hayes N, Shinn LM. Illicit online marketing of lorcaserin before DEA scheduling. Obesity (Silver Spring). 2013;21:861\u20134.","journal-title":"Obesity (Silver Spring)."},{"key":"206_CR56","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1467-789X.2010.00828.x","volume":"11","author":"RV Dvorak","year":"2010","unstructured":"Dvorak RV, Sharma AM, Astrup A. Antiobesity drugs: to be or not to be? Obes Rev. 2010;11:833\u20134.","journal-title":"Obes Rev."},{"issue":"Suppl. 4","key":"206_CR57","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/sj.ijo.0800915","volume":"23","author":"V Hainer","year":"1999","unstructured":"Hainer V. How should the obese patient be managed? Possible approaches to a national obesity management network. Int J Obes Relat Metab Disord. 1999;23(Suppl. 4):S14\u20138.","journal-title":"Int J Obes Relat Metab Disord."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0206-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-014-0206-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-014-0206-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T11:25:57Z","timestamp":1565695557000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-014-0206-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s40264-014-0206-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,6]]}}}